Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates-Reference-Cited by-同舟云学术

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates

Published:2022-01-22 Issue: Volume: Page:
ISSN:1462-8910
Container-title:Colorectal Disease
language:en
Short-container-title:Colorectal Disease

Author:

Eberhardson Michael¹²³^ORCID,Myrelid Pär⁴⁵^ORCID,Söderling Jonas K.⁶,Ekbom Anders⁶,Everhov Åsa H.⁶⁷,Hedin Charlotte R. H.²⁸,Neovius Martin⁶,Ludvigsson Jonas F.⁹¹⁰¹¹¹²,Olén Ola⁶⁷,Strid Hans,Hjortswang Henrik,Olsson Malin,Björk Jan,Bengtsson Jonas L.,Halfvarson Jonas,Andersson Marie A.,Karling Pontus,Rejler Martin,Jäghult Susanna,Fagerberg Ulrika L.,Grip Olof,Nordenvall Caroline,

Affiliation:

1. Department of Gastroenterology and Hepatology University Hospital Linköping Sweden

2. Department of Medicine Solna Karolinska Institutet Stockholm Sweden

3. Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden

4. Division of Surgery Department of Biomedical and Clinical Sciences Faculty of Health Sciences Linköping University Linköping Sweden

5. Department of Surgery University Hospital Linköping Sweden

6. Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm Sweden

7. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet Stockholm Sweden

8. Division of Gastroenterology Medical Unit Gastroenterology, Dermatovenereology and Rheumatology Karolinska University Hospital Stockholm Sweden

9. Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden

10. Department of Pediatrics Örebro University Hospital Örebro Sweden

11. Division of Epidemiology and Public Health School of Medicine University of Nottingham Nottingham UK

12. Department of Medicine Columbia University College of Physicians and Surgeons New York New York USA

Funder

Stockholms Läns Landsting

Vetenskapsrådet

Karolinska Institutet

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/codi.16021

Reference43 articles.

1. Adalimumab Induces Deep Remission in Patients With Crohn's Disease

2. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

3. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

4. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment

5. Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study;Alimentary Pharmacology & Therapeutics;2024-04-14

2. Crossing barriers: the burden of inflammatory bowel disease across Western Europe;Therapeutic Advances in Gastroenterology;2023-01

3. Smoking Is Not an Independent Risk Factor for Surgery in Patients with Crohn’s Disease on Biologic Therapy;Inflammatory Intestinal Diseases;2023

4. A systematic description of continent ileostomy revision techniques;International Journal of Colorectal Disease;2022-11-21

5. Nestin+ Peyer's patch resident MSCs enhance healing of inflammatory bowel disease through IL ‐22‐mediated intestinal epithelial repair;Cell Proliferation;2022-11-20